SGLT-2 inhibitor and GLP-1 receptor agonist drugs should be used in all or almost all adults with type 2 diabetes at higher ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

The agency shared information from reports by users of compounded semaglutide and tirzepatide who have experienced health ...

A Cell Metabolism study reveals that GIPR signaling in oligodendrocytes enhances brain access and weight-loss efficacy of GLP ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

Insurance companies are increasingly restricting coverage for GLP-1 medications, impacting patient access and affordability.

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight increase in new diabetic retinopathy cases but fewer severe eye complications, ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) without considering cardiovascular and kidney risks, according to a BMJ ...

Semaglutide and similar peptide drugs bind the G-protein coupled GLP-1 receptor to transfer chemical signals from outside the ...

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...